IRVINE, Calif., Sept. 22, 2005 (PRIMEZONE) -- "Amid what appears to be breakthrough after breakthrough and facing domestic crises as a result of hurricanes that have destroyed parts of the south while simultaneously injuring the presidents' approval numbers, one wonders if President Bush can afford to oppose controversial elements of stem cell research," stated SmallCap Sentinel analyst D.R. Clark. "The recent breakthrough in the rehabilitation of paralyzed mice walking again as a result of human stem cells paints a rosy picture of the possibilities. Can Bush afford to be viewed as a president who is opposed to any element of this study?"
"Already leading republican Senators Frist and Spector have broken ranks publicly with the president on his desire to limit funding for embryonic stem cell research," Clark added. "With the president drawing fire from many over the handling of the Katrina disaster -justified or not- it might not be the time for the president to fight the stem cell battle within his party and beyond."
An informational report titled "Looking at the Political Impact on Stem Cell Research" has been made available free of charge via financial courier StockUpTicks.com at www.SmallCapSentinel.com
The report will address New Life Scientific (OTCBB:NWLF), which endeavors to blend Eastern European research & development with Western management, Stemcells Inc. (Nasdaq:STEM) which recently announced success in enabling once paralyzed mice to walk again, Aastrom Biosciences Inc. (Nasdaq:ASTM), and Geron Corp. (Nasdaq: GERN).
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid thirty-six hundred dollars for preparation and distribution of this report and other advertising services by Emerging Markets Consulting LLC. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.